Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity
- 1 July 1991
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 78 (3), 390-397
- https://doi.org/10.1111/j.1365-2141.1991.tb04453.x
Abstract
Carrier and prenatal diagnosis based on the identification of the gene defect (direct diagnosis) increases the proportion of haemophilia B families that can be offered precise genetic counselling from the 50-60% attainable by DNA markers, to 100%, and they also provide information on the molecular biology of the disease. We propose that in order to maximize the practical and scientific benefits of direct diagnosis the gene defect of complete (possibly national) populations of patients should be characterized and the information stored in appropriate confidential databases. We demonstrate the feasibility of such a strategy by characterizing the mutations of all the patients registered with the Malmo haemophilia centre. These patients (44♂ and 1♀) are from 45 unrelated families and 24 (53%) have negative family history. The 25 patients with similar reduction of factor IX:C and factor IX:Ag (24♂ + 1♀) have: two gross deletions, three frameshifts, four translation stops, six mutations expected to affect pre-mRNA splicing and 10 amino acid substitutions. The six patients with greater reduction of factor IX:C than factor IX:Ag and the seven with reduced IX:C and normal IX:Ag have only amino acid substitutions. Patients with inhibitors have: one complete deletion, one frameshift and three translation stops. One patient has both a translation stop and a functionally neutral amino acid substitution (His257→Tyr). Characterization of the factor IX mutation was successful in every case, usually entailed 4 person-days work, and has led to the identification of 12 amino acid residues essential for the factor IX structure and functionKeywords
This publication has 38 references indexed in Scilit:
- Direct sequencing of the activation peptide and the catalytic domain of the factor IX gene in six speciesGenomics, 1990
- The organization of 3' splice-site sequences in mammalian introns.Genes & Development, 1989
- Single base mismatches in DNA long- and short-range structure probed by analysis of axis trajectory and local chemical reactivityJournal of Molecular Biology, 1989
- DETECTION OF POLYMORPHISMS AT CYTOSINE PHOSPHOGUANADINE DINUCLEOTIDES AND DIAGNOSIS OF HAEMOPHILIA B CARRIERSThe Lancet, 1989
- Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position −4Cell, 1986
- Cause of the ‘inhibitor’ phenotype in the haemophiliasNature, 1986
- Specific and stable intron-factor interactions are established early during in vitro pre-mRNA splicingCell, 1985
- Complete nucleotide sequences of the gene for human factor IX (antihemophilic factor B)Biochemistry, 1985
- Cryptic branch point activation allows accurate in vitro splicing of human β-globin intron mutantsCell, 1985
- Gene deletions in patients with haemophilia B and anti-factor IX antibodiesNature, 1983